No Data Yet
Guardant Health will present 14 studies at the 2025 San Antonio Breast Cancer Symposium on its liquid biopsy tests for breast cancer, aiming to validate their use in predicting recurrence and guiding treatment, positioning the company in the competitive oncology diagnostics market.
Guardant Health has partnered with Italy's Policlinico Gemelli to launch an in-house liquid biopsy service, embedding its advanced cancer diagnostics directly within a major European hospital. This move aims to accelerate turnaround times and improve access to precision oncology for patients with advanced cancer.
Guardant Health is partnering with Trial Library to integrate its precision oncology diagnostics with an AI-powered platform, aiming to broaden patient access to U.S. cancer clinical trials and streamline enrollment.
Portfolio
